Biogen, Alcyone in agreement for medical device for antisense oligonucleotide therapies
herraez



Biogen (NASDAQ:BIIB) and Alcyone Therapeutics are in a licensing and collaboration agreement to develop the latter's ThecaFlex DRx System, an implantable medical device for subcutaneous delivery of antisense oligonucleotide (ASO) therapies.
Terms call for Biogen (BIIB) to make an upfront payment of $10M in exchange for an exclusive global license to ThecaFlex DRx for spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis indications, and a co-exclusive global license in an undisclosed indication. Alcyone is also eligible for up to $41M in milestone payments.

ThecaFlex DRx will initially be examined with Biogen's (BIIB) Spinraza (nusinersen) in SMA. The two companies will jointly collaborate on clinical development of ThecaFlex DRx System for ASO therapies, and Alcyone will be solely responsible for its manufacture and commercialization.
Biogen (BIIB) has a Jan. 6 PDUFA date for its Alzheimer's therapy lecanemab.